Vanguard Investments Australia
GLUE icon

Vanguard Investments Australia’s Monte Rosa Therapeutics GLUE Stock Holding History

Vanguard Investments Australia’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Hold
8,851
– – ﹤0.01% 2086
2026
Q1 		$146K Buy
+8,851
New +$169K ﹤0.01% 2167

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Investments Australia's GLUE Position: Q2 2026 in Review

Vanguard Investments Australia held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 8,851 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

Vanguard Investments Australia first reported a position in GLUE in Q1 2026 and has held it in 2 quarters since. 175 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Vanguard Investments Australia held 8,851 shares of Monte Rosa Therapeutics worth $214K as of Q2 2026.
  • Vanguard Investments Australia left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2086 holding.
  • Vanguard Investments Australia first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 175 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.